Non-Animal Models (NAMs) in Practice: Approaches for Preclinical Safety and Efficacy Screening

Ce webinaire couvrira

UK, US, and EU perspectives on New Approach Methodologies.

Case studies spanning:

Whole blood bioassays.
Isolated primary immune cell assays.
Our ex vivo skin explant platform.
Reconstructed skin models for efficacy and tolerance tests.
Applications of precision cut lung slices for respiratory research without animal testing.

S'inscrire pour s'enregistrer

Date : 2026-10-15

Le temps : 11:00 AM (EDT)

Langue : English

Frais : Free

Thèmes : Lab Testing

Intervenants : Kelsey Retting, Arnaud Huard, Callum O Kane

Créer mon compte

Ce que vous apprendrez

Join us on October 15, 2026 (1700 CEST / 1500 UTC) for our live webinar: Non-Animal Models in Practice: Approaches for Preclinical Safety and Efficacy Screening.

In this webinar, we’ll cover:

The history and status of NAMs in EU, UK, and US preclinical testing.
Ex vivo platform data from human blood bioassays.
Dermal safety and efficacy testing without animal models.
Respiratory indication testing using human-relevant alternatives.

Equip your team with a clearer view of where non-animal approaches really stand today, and where they may head next.

A propos des intervenants

Kelsey Retting

Senior BD Manager, QIMA Life Sciences

Kelsey is a Senior Business Development Manager at QIMA Life Sciences with a PhD in Biological Chemistry from UCLA and a career spanning drug discovery, in vitro pharmacology, and translational research. She has worked across large pharmaceutical companies, biotechnology firms, and start-ups, developing assays and complex 3D tissue-engineered and bioprinted models for disease modeling, compound screening, and preclinical development.

Arnaud Huard

Study Director, QIMA Bioalternatives

Arnaud is a study directeur at QIMA Bioalternatives, specialised in immuno-inflammation research. He achieved a PhD on resolution of inflammation in Frankfurt, followed by two postdocs in Geneva, working on skin inflammation, psoriasis and inflammasome biology, in the context of hyperinflammatory syndrome.

Callum O Kane

Market Segment Lead, QIMA Life Sciences

Callum began his research career at Queen's University Belfast, gaining a PhD in pathogen epigenetics, before joining the Axis Bio science team. He spent five years with Axis, leading cell culture projects and R&D, and acting as study director for in vivo and in vitro research projects, before joining QIMA Life Sciences.

Pour en savoir plus

À propos de l'organisation

QIMA est reconnu comme l'un des leaders mondiaux du contrôle qualité et des solutions de conformité. Nous aidons les entreprises à fabriquer des produits auxquels les consommateurs peuvent faire confiance, grâce aux inspections qualité, aux tests en laboratoire, aux audits et à la certification. En combinant l'expertise humaine sur le terrain avec une technologie innovante, QIMA accompagne plus de 30 000 entreprises dans les secteurs des biens de consommation, de l'agroalimentaire, des cosmétiques et des soins personnels, ainsi que de la pharmacie et des biotechnologies, dans plus de 100 pays.

Webinaires connexes

Voir tout